Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

ncome of $2.9 million, or $0.11 cents per diluted share for the fourth quarter and a net loss of $10.3 million, or $0.39 cents per share for fiscal 2008. For the comparable periods of fiscal 2007, the amounts were a net loss of $10.8 million, or $0.42 cents per share, and a net loss of $51.2 million, or $2.01 cents per share.

Balance sheet and cash flow

Cash balances have increased by $1.1 million to $91.1 million since the end of the third quarter, and by $6.3 million since the prior fiscal year end of April 27, 2007. The increase in the most recent quarter reflects positive operating cash flow of $7.4 million, offset by the repurchase of 479,000 shares of common stock for $6.2 million.

On April 21, 2008 the company announced the settlement of litigation regarding the $125 million convertible notes. The settlement grants the note holders an option to redeem the notes on December 27, 2011, nine months earlier than the original maturity date. Accordingly, the company has now reclassified this liability to long-term.

Depression update

The company previously announced an effort to identify a financial partner to assist in the execution of the clinical plan developed for the depression indication. This effort remains ongoing, and any progress will be announced at the appropriate time.

Objectives

"During fiscal 2008 the company made significant progress on the objectives outlined by the Board in February 2007," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "In particular, the company has now recorded operating earnings and positive cash flow from operations for the last two quarters of fiscal 2008, and net earnings in the recently completed fourth quarter. Our core U.S. epilepsy business has shown growth for three consecutive quarters, culminating in approximately 20% volume growth in the fourth quarter over the prior year, and our international operations have posted another record year with annu
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Philadelphia, Pa. (PRWEB) September 22, 2014 ... develops rapid diagnostics for the food and beverage ... assay will be distributed under a non-exclusive agreement ... products and services. , Enartis, an Esseco Group ... BRETT to winemakers in California and other global ...
(Date:9/22/2014)... The US markets on Friday, September 19, ... Jones Industrial Average finished at 17,279.74, up 0.08% and ... S&P 500 finished the session 0.05% lower at 2,010.40. ... finished on a positive note. The S&P 500 Health ... 0.10%, with the index gaining 6.95% in the previous ...
(Date:9/21/2014)... time, scientists have discovered how to produce ultra-thin "diamond ... greater than that of today,s strongest nanotubes and polymers. ... led by John V. Badding, a professor of chemistry ... 21 September 2014 issue of the journal Nature ... our discovery is intriguing because the threads we formed ...
(Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
Breaking Biology Technology:Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... 2011 Pharmaceutical organizations rely heavily on internal ... Faced with a constantly evolving communication environment, companies ... with the most appropriate tactic. It ... is the most effective approach for the many ...
... discovery of a new class of dual-acting antimalarial compounds - ... Science online, at the Science Express website ... and blood infections, attacking the Plasmodium parasite at both stages ... how scientists developed a novel assay to determine liver stage ...
... Today BioSpace , the leading life sciences employment ... Campaign , marking the 7th edition. ... highlights leading organizations across the northwestern United States and ... electronic and printed campaign map that is ...
Cached Biology Technology:Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 3BioSpace Spotlights Northwest's Life Science Community 2
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/21/2014)... barnacles secrete very sticky proteins that help them cling ... these natural adhesives, a team of MIT engineers has ... ships or help heal wounds and surgical incisions. , ... engineered bacteria to produce a hybrid material that incorporates ... protein found in biofilms slimy layers formed by ...
(Date:9/19/2014)... Jimmy Durante of dinosaurs a newly discovered ... new dinosaur, named Rhinorex condrupus by ... Young University, lived in what is now Utah ... Cretaceous period. , Rhinorex, which translates roughly into ... relative of other Cretaceous hadrosaurs like Parasaurolophus and ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3New hadrosaur noses into spotlight 2
... The U.S. Department of Energys Office of Science ... publication, Facilities for the Future of Science: A Twenty-Year ... in deploying the scientific facilities and instruments that the ... the frontiers of science and support the Departments missions. ...
... -- Growing recognition of the importance of health as ... has prompted the Proceedings of the National Academy of ... Health to its existing section on Sustainable Development. The ... editorial by Barry R. Bloom, Dean of the Harvard ...
... has published recent findings that reveal some of the factors underlying ... The paper, Stem Cell Aging is Controlled both Intrinsically and ... issue of Cell Stem Cell. Lei Pan, Predoctoral Researcher, and Ting ... respectively. It is widely ...
Cached Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5Data on life expectancy show many countries clustered in high mortality traps 2Data on life expectancy show many countries clustered in high mortality traps 3Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2